all report title image

CELL PROCESSING MARKET ANALYSIS

Cell Processing Market, by Product Type (Equipment, Consumables, and Software), by End User (Hospitals, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, and Academic Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

  • To Be Published : Sep 2024
  • Code : CMI2518
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

Market Challenges And Opportunities

Global Cell Processing Market: Drivers

The global cell processing market size is expected to increase, owing to rising demand for cell therapy. Cell therapy is the only curative treatment for many diseases such as cancer, autoimmune disease, and neural disease. According to the Worldwide Network for Blood and Marrow Transplantation (WBMT), in 2012, around one million stem cell transplantations were performed, worldwide.

Continuous research and development for new innovative techniques for cell isolation, concentration, and preservation is another major factor driving the cell processing market size. According to University of California, Los Angeles (UCLA) 2016 research report, researchers have developed a new magnetic ratcheting system to separate and organize cells suspended in fluid samples by their subtle biochemical differences. The system sorts cells more quickly and accurately and perform simple, rapid automation of cell analysis and can separate therapeutic cells from non-therapeutic cells.

Global Cell Processing Market: Restraints

The major restraining factors affecting the cell processing market revenue includes safety issues for patients, commercialization of cells. It also includes safety issues for preservation and distribution of cells or customized cell therapies for patients. Failures of stem cell therapy trials due to stringent rules and regulations also hamper the cell processing market growth. For instance, in 2014, a U.S.-based company Athersys Inc. along with Pfizer conducted a clinical trial on stem cell product Multistem infusion in patients with ulcerative colitis. The trial failed to meet efficacy end points from the FDA in interim analysis.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.